NLGN4X and glioblastoma: Notably, four peptides SILDIVTKV (RFTN2), AIIDGVESV (PTPRZ1), KVFAGIPTV (PTPRZ1), and NLDTLMTYV (NLGN4X) (Supplementary Table 2) were also reported as immunogenic in patients with GBM providing strong evidence that these peptides should also be explored in patients with HLA-A2+ DIPG (29, 56).